ArticleClinical oral investigations2025
Oral mucosal lesions in children with severe asthma and acute respiratory viral infections.
Article in Clinical oral investigations, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
background/purposeThis study investigated the clinical and histological characteristics of oral mucosal lesions in children with acute respiratory viral infections (ARVI) and Asthma (BA)-conditions that frequently coexist and exacerbate mucosal damage. MATERIALS AND
methodsThe rationale for the study stems from the lack of comprehensive data on the combined impact of these diseases on oral health. A total of 200 children aged 5-12 years were examined in a hospital setting and divided into 4 equal groups: children with ARVI (Group 1), children with Asthma (Group 2), children with both conditions (Group 3), and healthy children (control Group 4). The experimental design included clinical assessment, mucosal biopsy, histological examination, and quality-of-life evaluation using validated questionnaires.
resultsResults showed that children in Group 3 (ARVI + BA) exhibited significantly more severe mucosal damage, including pronounced hyperemia (3.0 ± 0.5), increased erosions (4.5 ± 1.1), and higher pain scores (3.5 ± 0.6) compared to Groups 1 and 2. The control group (Group 4) showed minimal changes. Histological analysis revealed greater epithelial atrophy and inflammatory infiltration in Group 3.
conclusionsThese findings highlight the need for tailored therapeutic approaches in children with coexisting ARVI and Asthma to mitigate oral mucosal damage and improve overall health outcomes. The study addressed the lack of comprehensive data on the combined effects of ARVI and asthma on oral health, with findings revealing more pronounced mucosal damage in children with both conditions compared to those with only one.
Indexed as
Identifiers
40892104What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.